Troglitazone suppresses telomerase activity independently of PPARγ in estrogen-receptor negative breast cancer cells
<p>Abstract</p> <p>Background</p> <p>Breast cancer is one the highest causes of female cancer death worldwide. Many standard chemotherapeutic agents currently used to treat breast cancer are relatively non-specific and act on all rapidly dividing cells. In recent years,...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2010-07-01
|
| Series: | BMC Cancer |
| Online Access: | http://www.biomedcentral.com/1471-2407/10/390 |
| _version_ | 1818012157044850688 |
|---|---|
| author | Nguyen Johnny Taboski Michael AS Rashid-Kolvear Fariborz Wang Dong-Yu Harrington Lea A Done Susan J |
| author_facet | Nguyen Johnny Taboski Michael AS Rashid-Kolvear Fariborz Wang Dong-Yu Harrington Lea A Done Susan J |
| author_sort | Nguyen Johnny |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>Breast cancer is one the highest causes of female cancer death worldwide. Many standard chemotherapeutic agents currently used to treat breast cancer are relatively non-specific and act on all rapidly dividing cells. In recent years, more specific targeted therapies have been introduced. It is known that telomerase is active in over 90% of breast cancer tumors but inactive in adjacent normal tissues. The prevalence of active telomerase in breast cancer patients makes telomerase an attractive therapeutic target. Recent evidence suggests that telomerase activity can be suppressed by peroxisome proliferator activated receptor gamma (PPARγ). However, its effect on telomerase regulation in breast cancer has not been investigated.</p> <p>Methods</p> <p>In this study, we investigated the effect of the PPARγ ligand, troglitazone, on telomerase activity in the MDA-MB-231 breast cancer cell line. Real time RT-PCR and telomerase activity assays were used to evaluate the effect of troglitazone. MDA-MB-231 cells had PPARγ expression silenced using shRNA interference.</p> <p>Results</p> <p>We demonstrated that troglitazone reduced the mRNA expression of hTERT and telomerase activity in the MDA-MB-231 breast cancer cell line. Troglitazone reduced telomerase activity even in the absence of PPARγ. In agreement with this result, we found no correlation between PPARγ and hTERT mRNA transcript levels in breast cancer patients. Statistical significance was determined using Pearson correlation and the paired Student's <it>t </it>test.</p> <p>Conclusions</p> <p>To our knowledge, this is the first time that the effect of troglitazone on telomerase activity in breast cancer cells has been investigated. Our data suggest that troglitazone may be used as an anti-telomerase agent; however, the mechanism underlying this inhibitory effect remains to be determined.</p> |
| first_indexed | 2024-04-14T06:16:31Z |
| format | Article |
| id | doaj.art-102ad5de34024105855cb8562c528541 |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-04-14T06:16:31Z |
| publishDate | 2010-07-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-102ad5de34024105855cb8562c5285412022-12-22T02:08:10ZengBMCBMC Cancer1471-24072010-07-0110139010.1186/1471-2407-10-390Troglitazone suppresses telomerase activity independently of PPARγ in estrogen-receptor negative breast cancer cellsNguyen JohnnyTaboski Michael ASRashid-Kolvear FariborzWang Dong-YuHarrington Lea ADone Susan J<p>Abstract</p> <p>Background</p> <p>Breast cancer is one the highest causes of female cancer death worldwide. Many standard chemotherapeutic agents currently used to treat breast cancer are relatively non-specific and act on all rapidly dividing cells. In recent years, more specific targeted therapies have been introduced. It is known that telomerase is active in over 90% of breast cancer tumors but inactive in adjacent normal tissues. The prevalence of active telomerase in breast cancer patients makes telomerase an attractive therapeutic target. Recent evidence suggests that telomerase activity can be suppressed by peroxisome proliferator activated receptor gamma (PPARγ). However, its effect on telomerase regulation in breast cancer has not been investigated.</p> <p>Methods</p> <p>In this study, we investigated the effect of the PPARγ ligand, troglitazone, on telomerase activity in the MDA-MB-231 breast cancer cell line. Real time RT-PCR and telomerase activity assays were used to evaluate the effect of troglitazone. MDA-MB-231 cells had PPARγ expression silenced using shRNA interference.</p> <p>Results</p> <p>We demonstrated that troglitazone reduced the mRNA expression of hTERT and telomerase activity in the MDA-MB-231 breast cancer cell line. Troglitazone reduced telomerase activity even in the absence of PPARγ. In agreement with this result, we found no correlation between PPARγ and hTERT mRNA transcript levels in breast cancer patients. Statistical significance was determined using Pearson correlation and the paired Student's <it>t </it>test.</p> <p>Conclusions</p> <p>To our knowledge, this is the first time that the effect of troglitazone on telomerase activity in breast cancer cells has been investigated. Our data suggest that troglitazone may be used as an anti-telomerase agent; however, the mechanism underlying this inhibitory effect remains to be determined.</p>http://www.biomedcentral.com/1471-2407/10/390 |
| spellingShingle | Nguyen Johnny Taboski Michael AS Rashid-Kolvear Fariborz Wang Dong-Yu Harrington Lea A Done Susan J Troglitazone suppresses telomerase activity independently of PPARγ in estrogen-receptor negative breast cancer cells BMC Cancer |
| title | Troglitazone suppresses telomerase activity independently of PPARγ in estrogen-receptor negative breast cancer cells |
| title_full | Troglitazone suppresses telomerase activity independently of PPARγ in estrogen-receptor negative breast cancer cells |
| title_fullStr | Troglitazone suppresses telomerase activity independently of PPARγ in estrogen-receptor negative breast cancer cells |
| title_full_unstemmed | Troglitazone suppresses telomerase activity independently of PPARγ in estrogen-receptor negative breast cancer cells |
| title_short | Troglitazone suppresses telomerase activity independently of PPARγ in estrogen-receptor negative breast cancer cells |
| title_sort | troglitazone suppresses telomerase activity independently of pparγ in estrogen receptor negative breast cancer cells |
| url | http://www.biomedcentral.com/1471-2407/10/390 |
| work_keys_str_mv | AT nguyenjohnny troglitazonesuppressestelomeraseactivityindependentlyofpparginestrogenreceptornegativebreastcancercells AT taboskimichaelas troglitazonesuppressestelomeraseactivityindependentlyofpparginestrogenreceptornegativebreastcancercells AT rashidkolvearfariborz troglitazonesuppressestelomeraseactivityindependentlyofpparginestrogenreceptornegativebreastcancercells AT wangdongyu troglitazonesuppressestelomeraseactivityindependentlyofpparginestrogenreceptornegativebreastcancercells AT harringtonleaa troglitazonesuppressestelomeraseactivityindependentlyofpparginestrogenreceptornegativebreastcancercells AT donesusanj troglitazonesuppressestelomeraseactivityindependentlyofpparginestrogenreceptornegativebreastcancercells |